针对与1型糖尿病相关的柯萨奇B病毒(CVBs)的多价疫苗PRV-101的安全性、耐受性和免疫原性:一项双盲随机安慰剂对照I期试验
这项双盲随机安慰剂对照I期试验在芬兰单中心纳入32名18-44岁健康成人,随机接受低剂量(n=12)或高剂量(n=12)PRV-101多价灭活CVB疫苗(含血清型1-5)或安慰剂(n=8),于第0、4、8周肌内注射并随访24周。结果显示无严重不良事件或导致停药的不良事件,PRV-101诱导针对全部5种血清型的剂量依赖性中和抗体应答,>90%受试者在整个随访期对所有5种血清型均达到保护性滴度≥8。
要点
- PRV-101多价CVB疫苗在I期试验中耐受性良好,无严重不良事件或导致停药的不良事件。
- 与药物相关的不良事件在安慰剂组为37.5%、PRV-101组为62.5%,最常见为注射部位疼痛、头痛、注射部位不适和瘙痒。
- PRV-101诱导针对疫苗所含全部5种CVB血清型的剂量依赖性中和抗体应答,>90%受试者全程保护性滴度≥8。
核心结论
- 结果表明受试的多价CVB疫苗耐受性良好且具有免疫原性,支持其进一步临床开发。
研究设计与样本
- 双盲随机安慰剂对照I期试验,在芬兰单中心纳入32名18-44岁健康成人(17男、15女),随机接受低剂量PRV-101(n=12)、高剂量PRV-101(n=12)或安慰剂(n=8),于第0、4、8周肌内注射,随后随访24周。
- 主要纳入标准为一般健康状况良好、年龄18-45岁、签署书面知情同意并愿意遵守所有试验程序;治疗分配基于计算机生成的随机化方案,结局评估者对分组设盲。
- 主要终点为安全性和耐受性;采用ELISA和中和蚀斑减少试验分别分析抗CVB IgG和病毒中和滴度。
主要发现
- 32名受试者中未观察到严重不良事件或导致研究治疗中止的不良事件。
- 认为与研究药物相关的不良事件在安慰剂组发生率为37.5%,在PRV-101组为62.5%,最常见为注射部位疼痛、头痛、注射部位不适和注射部位瘙痒。
- PRV-101在高剂量组和低剂量组均诱导针对疫苗所含全部5种CVB血清型的剂量依赖性中和抗体应答。
- 在整个随访期间,>90%的受试者对所有5种血清型均达到保护性滴度≥8。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Infection with coxsackie B viruses (CVBs) can cause diseases ranging from mild common cold-type symptoms to severe life-threatening conditions. CVB infections are considered to be prime candidates for environmental triggers of type 1 diabetes. This, together with the significant disease burden of acute CVB infections and their association with chronic diseases other than diabetes, has prompted the development of human CVB vaccines. The current study evaluated the safety and immunogenicity of the first human vaccine designed against CVBs associated with type 1 diabetes in a double-blind randomised placebo-controlled Phase I trial. METHODS: The main eligibility criteria for participants were good general health, age between 18 and 45 years, provision of written informed consent and willingness to comply with all trial procedures. Treatment allocation (PRV-101 or placebo) was based on a computer-generated randomisation schedule and people assessing the outcomes were masked to group assignment. In total, 32 participants (17 men, 15 women) aged 18-44 years were randomised to receive a low (n=12) or high (n=12) dose of a multivalent, formalin-inactivated vaccine including CVB serotypes 1-5 (PRV-101), or placebo (n=8), given by intramuscular injections at weeks 0, 4 and 8 at a single study site in Finland. The participants were followed for another 24 weeks. Safety and tolerability were the primary endpoints. Anti-CVB IgG and virus-neutralising titres were analysed using an ELISA and neutralising plaque reduction assays, respectively. RESULTS: Among the 32 participants (low dose, n=12; high dose, n=12; placebo, n=8) no serious adverse events or adverse events leading to study treatment discontinuation were observed. Treatment-emergent adverse events considered to be related to the study drug occurred in 37.5% of the participants in the placebo group and 62.5% in the PRV-101 group (injection site pain, headache, injection site discomfort and injection site pruritus being most common). PRV-101 induced dose-dependent neutralising antibody responses against all five CVB serotypes included in the vaccine in both the high- and low-dose groups. Protective titres ≥8 against all five serotypes were seen in >90% of participants over the entire follow-up period. CONCLUSIONS/INTERPRETATION: The results indicate that the tested multivalent CVB vaccine is well tolerated and immunogenic, supporting its further clinical development. TRIAL REGISTRATION: ClinicalTrials.gov NCT04690426. FUNDING: This trial was funded by Provention Bio, a Sanofi company.
引用
- Hyöty H, Kääriäinen S, Laiho JE, et al. Safety, tolerability and immunogenicity of PRV-101, a multivalent vaccine targeting coxsackie B viruses (CVBs) associated with type 1 diabetes: a double-blind randomised placebo-controlled Phase I trial. Diabetologia. 2024. PMID: 38369573. doi:10.1007/s00125-024-06092-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。